| Drug General Information |
| Drug ID |
D0A1ZQ
|
| Former ID |
DCL000342
|
| Drug Name |
SU-6668
|
| Drug Type |
Small molecular drug
|
| Indication |
Advanced solid tumor [ICD9: 140-199; ICD10:C00-C75, C7A, C7B]
|
Phase 1 |
[1],
[2]
|
|---|
| Therapeutic Class |
Anticancer Agents
|
| Company |
Pfizer; Sugen
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C18H18N2O3
|
| InChI |
InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9-
|
| InChIKey |
NHFDRBXTEDBWCZ-ZROIWOOFSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
527809, 8034459, 11061326, 12015385, 14874233, 39301724, 53787898, 57287542, 57361293, 75555598, 81049299, 89388569, 99437172, 103175695, 113911629, 124757275, 125164079, 134338996, 134339167, 134964221, 135134779, 135182126, 135698723, 136340186, 136348238, 136367533, 136367774, 142063014, 143497361, 152234911, 152258241, 152344216, 160647077, 162011789, 162037617, 162202670, 163685934, 174561004, 177748855, 180386845, 185964372, 198939270, 204362248, 223366147, 223379505, 223705143, 226502638, 241376394, 242060022, 243278051
|
| Target and Pathway |
| Target(s) |
Platelet-derived growth factor receptor |
Target Info |
Inhibitor |
[3],
[4]
|
|---|
| Vascular endothelial growth factor receptor 2 |
Target Info |
Inhibitor |
[3],
[4]
|
| Aurora kinase A |
Target Info |
Inhibitor |
[3],
[4]
|
| Basic fibroblast growth factor receptor 1 |
Target Info |
Inhibitor |
[3],
[4]
|
| Aurora kinase B |
Target Info |
Inhibitor |
[3],
[4]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
VEGF signaling pathway
|
|
Focal adhesion
|
|
Proteoglycans in cancerhsa04114:Oocyte meiosishsa04010:MAPK signaling pathway
|
|
Adherens junction
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Regulation of actin cytoskeleton
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
Prostate cancer
|
|
Melanoma
|
|
Central carbon metabolism in cancer
|
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_11:TCR Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
VEGF signaling pathwayP00005:Angiogenesis
|
|
FGF signaling pathway
|
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
S1P1 pathway
|
|
VEGF and VEGFR signaling network
|
|
Integrins in angiogenesis
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Notch-mediated HES/HEY networkaurora_b_pathway:Aurora B signaling
|
|
Signaling by Aurora kinases
|
|
Integrin-linked kinase signaling
|
|
PLK1 signaling events
|
|
Aurora A signalingglypican_1pathway:Glypican 1 network
|
|
Syndecan-4-mediated signaling events
|
|
N-cadherin signaling events
|
|
FGF signaling pathwayaurora_b_pathway:Aurora B signaling
|
|
Aurora C signaling
|
|
FOXM1 transcription factor network
|
|
Aurora A signaling
|
|
Reactome
|
Neurophilin interactions with VEGF and VEGFR
|
|
VEGF binds to VEGFR leading to receptor dimerization
|
|
Integrin cell surface interactions
|
|
EPHA-mediated growth cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
VEGFR2 mediated cell proliferationR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
|
|
Regulation of PLK1 Activity at G2/M TransitionR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
|
|
Separation of Sister Chromatids
|
|
Resolution of Sister Chromatid Cohesion
|
|
RHO GTPases Activate Formins
|
|
Mitotic Prometaphase
|
|
WikiPathways
|
Focal Adhesion
|
|
Nifedipine Activity
|
|
Cardiac Progenitor Differentiation
|
|
Signaling by VEGF
|
|
AngiogenesisWP437:EGF/EGFR Signaling Pathway
|
|
JAK/STAT
|
|
Gastric Cancer Network 1
|
|
Integrated Breast Cancer Pathway
|
|
APC/C-mediated degradation of cell cycle proteinsWP51:Regulation of Actin Cytoskeleton
|
|
Endochondral Ossification
|
|
MAPK Signaling Pathway
|
|
Mesodermal Commitment Pathway
|
|
Hair Follicle Development: Induction (Part 1 of 3)
|
|
Integrated Pancreatic Cancer Pathway
|
|
Signaling Pathways in Glioblastoma
|
|
Neural Crest Differentiation
|
|
Signaling by FGFRWP2757:Mitotic Metaphase and Anaphase
|
|
Mitotic Prometaphase
|
|
Regulation of Microtubule Cytoskeleton
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
APC/C-mediated degradation of cell cycle proteins
|
| References |
| REF 1 | A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs. 2004 Nov;22(4):459-66. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7816). |
|---|
| REF 3 | Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clin Cancer Res. 2005 Sep 1;11(17):6240-6. |
|---|
| REF 4 | A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. |
|---|
